148 related articles for article (PubMed ID: 19890203)
1. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.
Pao VY; Lee GA; Taylor S; Aweeka FT; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
AIDS; 2010 Jan; 24(2):265-70. PubMed ID: 19890203
[TBL] [Abstract][Full Text] [Related]
2. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
[TBL] [Abstract][Full Text] [Related]
3. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
Noor MA; Flint OP; Maa JF; Parker RA
AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
[TBL] [Abstract][Full Text] [Related]
4. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
Dubé MP; Shen C; Greenwald M; Mather KJ
Clin Infect Dis; 2008 Aug; 47(4):567-74. PubMed ID: 18636958
[TBL] [Abstract][Full Text] [Related]
5. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
Lee GA; Rao M; Mulligan K; Lo JC; Aweeka F; Schwarz JM; Schambelan M; Grunfeld C
AIDS; 2007 Oct; 21(16):2183-90. PubMed ID: 18090045
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir-Ritonavir: a new protease inhibitor.
Mangum EM; Graham KK
Pharmacotherapy; 2001 Nov; 21(11):1352-63. PubMed ID: 11714208
[TBL] [Abstract][Full Text] [Related]
7. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
[TBL] [Abstract][Full Text] [Related]
8. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Stanley TL; Joy T; Hadigan CM; Liebau JG; Makimura H; Chen CY; Thomas BJ; Weise SB; Robbins GK; Grinspoon SK
AIDS; 2009 Jul; 23(11):1349-57. PubMed ID: 19474651
[TBL] [Abstract][Full Text] [Related]
9. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
Carr A; Ritzhaupt A; Zhang W; Zajdenverg R; Workman C; Gatell JM; Cahn P; Chaves R
AIDS; 2008 Nov; 22(17):2313-21. PubMed ID: 18981770
[TBL] [Abstract][Full Text] [Related]
10. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
Noor MA; Parker RA; O'Mara E; Grasela DM; Currie A; Hodder SL; Fiedorek FT; Haas DW
AIDS; 2004 Nov; 18(16):2137-44. PubMed ID: 15577646
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of indinavir in healthy HIV-seronegative men.
Noor MA; Lo JC; Mulligan K; Schwarz JM; Halvorsen RA; Schambelan M; Grunfeld C
AIDS; 2001 May; 15(7):F11-8. PubMed ID: 11399973
[TBL] [Abstract][Full Text] [Related]
12. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.
Lee GA; Lo JC; Aweeka F; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
Clin Infect Dis; 2006 Sep; 43(5):658-60. PubMed ID: 16886163
[TBL] [Abstract][Full Text] [Related]
13. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2003 May; 168(1):107-13. PubMed ID: 12732393
[TBL] [Abstract][Full Text] [Related]
14. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
Song I; Min SS; Borland J; Lou Y; Chen S; Patel P; Ishibashi T; Piscitelli SC
J Clin Pharmacol; 2011 Feb; 51(2):237-42. PubMed ID: 20489027
[TBL] [Abstract][Full Text] [Related]
15. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).
Lafeuillade A; Hittinger G; Philip G; Lambry V; Jolly P; Poggi C
HIV Clin Trials; 2004; 5(6):392-8. PubMed ID: 15682352
[TBL] [Abstract][Full Text] [Related]
16. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
[TBL] [Abstract][Full Text] [Related]
17. An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.
Randell P; Jackson A; Milinkovic A; Boffito M; Moyle G
Antivir Ther; 2017; 22(2):145-151. PubMed ID: 27708251
[TBL] [Abstract][Full Text] [Related]
18. Encouraging resistance data for Kaletra (lopinavir/ritonavir).
J Assoc Nurses AIDS Care; 2002; 13(3):108. PubMed ID: 12064017
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
20. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.
Samaras K; Richardson R; Carr A
AIDS; 2010 Jul; 24(11):1727-31. PubMed ID: 20588105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
